查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881479

非何杰金氏淋巴瘤市場－全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、藥物類別、給藥途徑、配銷通路、地區和競爭格局分類，2020-2030年預測

Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球非何杰金氏淋巴瘤市場規模為72.4億美元，預計到2030年將以7.72%的複合年成長率成長至113.1億美元。全球非何杰金氏淋巴瘤市場涵蓋一系列全面的診斷工具和治療手段，包括化療、標靶治療、免疫療法（如CAR-T細胞療法）、放射治療和幹細胞移植，這些療法均針對不同的淋巴瘤亞型量身定做。市場成長的主要促進因素是全球非何杰金氏淋巴瘤發病率的上升以及對標靶治療和免疫療法等先進治療方式日益成長的需求。

市場概覽
預測期 2026-2030
2024年市場規模 72.4億美元
2030年市場規模 113.1億美元
2025-2030年複合年成長率 7.72%
成長最快的細分市場 T細胞淋巴瘤
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球非何杰金氏淋巴瘤市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（B細胞淋巴瘤、T細胞淋巴瘤）
    • 依藥物類別（單株抗體、抗體藥物偶聯物、BTK/BCL-2激酶抑制劑、PI3激酶抑制劑、其他）
    • 依給藥途徑（口服、注射、其他）
    • 按配銷通路（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美非何杰金氏淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非何杰金氏淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非何杰金氏淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非霍奇金淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非何杰金氏淋巴瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球非何杰金氏淋巴瘤市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Seagen, Inc (Pfizer Inc.)
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Merck & Co. Inc

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21052

The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.24 Billion
Market Size 2030USD 11.31 Billion
CAGR 2025-20307.72%
Fastest Growing SegmentT-cell Lymphoma
Largest MarketNorth America

Key Market Drivers

The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY(R), for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.

Key Market Challenges

The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.

Key Market Trends

The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.

Key Market Players

  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Seagen, Inc (Pfizer Inc.)
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Merck & Co. Inc

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma Market, By Disease Type:

  • B-cell Lymphomas
  • T-cell Lymphoma

Non-Hodgkin Lymphoma Market, By Drug Class:

  • Monoclonal Antibodies
  • Antibody-Drug Conjugates
  • BTK/BCL-2 Kinase Inhibitors
  • PI3 Kinase Inhibitors
  • Others

Non-Hodgkin Lymphoma Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Non-Hodgkin Lymphoma Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Non-Hodgkin Lymphoma Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma Market.

Available Customizations:

Global Non-Hodgkin Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (B-cell Lymphomas, T-cell Lymphoma)
    • 5.2.2. By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Non-Hodgkin Lymphoma Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Hodgkin Lymphoma Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Non-Hodgkin Lymphoma Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Non-Hodgkin Lymphoma Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Hodgkin Lymphoma Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Non-Hodgkin Lymphoma Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Non-Hodgkin Lymphoma Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Non-Hodgkin Lymphoma Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Non-Hodgkin Lymphoma Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Hodgkin Lymphoma Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Non-Hodgkin Lymphoma Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Non-Hodgkin Lymphoma Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Non-Hodgkin Lymphoma Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Non-Hodgkin Lymphoma Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Hodgkin Lymphoma Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Non-Hodgkin Lymphoma Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Non-Hodgkin Lymphoma Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Hodgkin Lymphoma Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Non-Hodgkin Lymphoma Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Non-Hodgkin Lymphoma Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. AstraZeneca plc
  • 15.4. Johnson & Johnson Services, Inc.
  • 15.5. Novartis AG
  • 15.6. Seagen, Inc (Pfizer Inc.)
  • 15.7. Bayer AG
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Gilead Sciences Inc
  • 15.10. Merck & Co. Inc

16. Strategic Recommendations

17. About Us & Disclaimer